EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Role of monocarboxylate transporters in cancer immunology and their therapeutic potential

Ferdos Faghihkhorasani, Mona Moosavi, Al-Hasnawi Rasool Riyadh Abdulwahid, Mohammed Kavei, Soroush Karimi, Mahshid Seyed Karimi, Payam Vezvaei, Mahsa Manafi Varkiani, Amir Reza Aref, Nasim Ebrahimi

British Journal of Pharmacology · 2025-10 · 182 (19) · 4421-4457

DOI: 10.1111/bph.70110 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 30.07.2025. Verfasst von Ferdos Faghihkhorasani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Campus, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China. Hauptthemen laut MEDLINE: Monocarboxylic Acid Transporters, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 308 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monocarboxylate transporters (MCTs) affect cancer metabolism and the regulation of immune responses, making them targets for cancer therapy. This study examines the roles of MCTs, specifically MCT1 and MCT4, in various cancer types and their influence on the advancement of tumours, metastasis and patient prognosis. We analyse the interaction among MCTs, tumour microenvironments (TMEs) and the immune system, as biomarkers and targets for therapy. Initial clinical trials have demonstrated encouraging outcomes with MCT inhibitors, including AZD3965. The combination of MCT inhibition and immunotherapy, such as immune checkpoint blockade, has shown synergistic effects in boosting the antitumour responses of the body's immune system. This study reviews the importance of MCTs and their potential as new targets for enhancing cancer therapy efficacy, especially when used in conjunction with current medicine treatment regimes. In numerous malignancies, tumour cells form a metabolic symbiosis wherein glycolytic cells, marked by elevated MCT4 expression, secrete lactate into the TME, while oxidative cancer cells, expressing MCT1, absorb this lactate as a metabolic substrate for the tricarboxylic acid cycle. Disrupting this lactate shuttle through targeted inhibition of MCTs is a promising strategy to overcome immune evasion and enhance the efficacy of immunotherapies. Targeting monocarboxylate transporters (MCTs) in glycolytic and oxidative tumour cells enhances antitumour immunity. Combinational therapy using MCT1 inhibitors (e.g. AZD3965), MCT4 inhibitors and immune checkpoint blockade can suppress lactate‐mediated immunosuppression in the TME. By disrupting lactate shuttling between glycolytic and oxidative tumour cells, this strategy promotes T cell function and improves cancer treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monocarboxylic Acid TransportersNeoplasmsHumansAnimalsTumor MicroenvironmentImmunotherapyAntineoplastic AgentsMuscle ProteinsPyrimidinonesThiophenesSymportersMonocarboxylate Transport Protein 1

Stichwörter der Autor:innen

MCT inhibitorscancer metabolismcancer progressionimmunotherapytherapeutic targetstumour microenvironment

Substanzen

Monocarboxylic Acid TransportersAntineoplastic AgentsMuscle ProteinsPyrimidinonesThiophenesSymportersMonocarboxylate Transport Protein 1SLC16A4 protein, humanAZD3965

Autor:innen und Institutionen

  • Medical Campus, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
  • Department of Poultry Science, Tarbiat Modares University, Tehran, Iran.
  • Department of Biology, Faculty of Science, Arak University, Arak, Iran.
  • Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Department of Surgery and Anesthesiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Radiology Department, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Faghihkhorasani, F., Moosavi, M., Rasool Riyadh Abdulwahid, A. H., Kavei, M., Karimi, S., Seyed Karimi, M., Vezvaei, P., Manafi Varkiani, M., Aref, A. R., & Ebrahimi, N. (2025). Role of monocarboxylate transporters in cancer immunology and their therapeutic potential. British Journal of Pharmacology, 182(19), 4421-4457. https://doi.org/10.1111/bph.70110

Vancouver

Faghihkhorasani F, Moosavi M, Rasool Riyadh Abdulwahid AH, Kavei M, Karimi S, Seyed Karimi M, et al. Role of monocarboxylate transporters in cancer immunology and their therapeutic potential. British Journal of Pharmacology. 2025;182(19):4421-4457. doi:10.1111/bph.70110

BibTeX
@article{Faghihkhorasani2025,
  author = {Faghihkhorasani, Ferdos and Moosavi, Mona and Rasool Riyadh Abdulwahid, Al-Hasnawi and Kavei, Mohammed and Karimi, Soroush and Seyed Karimi, Mahshid and Vezvaei, Payam and Manafi Varkiani, Mahsa and Aref, Amir Reza and Ebrahimi, Nasim},
  title = {Role of monocarboxylate transporters in cancer immunology and their therapeutic potential},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {19},
  pages = {4421--4457},
  doi = {10.1111/bph.70110}
}
Kostenlos starten →